Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06143878 · ClinicalTrials.gov registry record · Phase 3
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study of Plaque Psoriasis, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 774
- Enrollment target
- 20
- Study locations
NCT06143878 is a Phase 3 study of Plaque Psoriasis that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 774 participants, above the 399-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (94% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT06143878, a Phase 3 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 774 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Conditions Studied
Interventions
- DRUG Deucravacitinib
- DRUG JNJ-77242113
- DRUG JNJ-77242113 Matching Placebo
- DRUG Deucravacitinib Matching Placebo
Study Locations (20)
California
- First OC Dermatology - Fountain Valley
- Center for Dermatology Clinical Research - Fremont
- Integrative Skin Science and Research - Sacramento
- Southern California Dermatology - Santa Ana
- Clinical Science Institute - Santa Monica
Florida
- Driven Research LLC - Coral Gables
- Ziaderm Research LLC - North Miami Beach
- Renstar Medical Research - Ocala
- Forcare Clinical Research Inc - Tampa
Illinois
- DeNova Research - Chicago
- Arlington Dermatology - Rolling Meadows
- Northshore Medical Group - Skokie
- Dundee Dermatology - West Dundee
Arizona
- Medical Dermatology Specialists - Phoenix
- Center for Dermatology and Plastic Surgery - Scottsdale
Georgia
- Hamilton Research LLC - Alpharetta
- Skin Care Physicians of Georgia - Macon
Indiana
- Dawes Fretzin Clinical Research Group LLC - Indianapolis
- Indiana Clinical Trial Center - Plainfield
Arkansas
- Johnson Dermatology - Fort Smith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 774 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06143878
The ClinicalTrials.gov registry entry for NCT06143878 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 774 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 399-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (94% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 4 interventions - of which Deucravacitinib is the first listed.
NCT06143878 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06143878 about?
NCT06143878 is a clinical study titled "A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis". The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
What is the current status of trial NCT06143878?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 774 participants. The study started on 2024-02-01. Estimated completion is 2027-06-01.
What conditions does trial NCT06143878 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT06143878?
The interventions under investigation include: Deucravacitinib (DRUG), JNJ-77242113 (DRUG), JNJ-77242113 Matching Placebo (DRUG), Deucravacitinib Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT06143878?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06143878 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.